KTOV Kitov Pharma Ltd.

0.34
+0.05  (+18%)
Previous Close 0.29
Open 0.31
Price To Book 1.32
Market Cap 13,756,217
Shares 40,105,588
Volume 7,377,638
Short Ratio
Av. Daily Volume 1,145,755
Stock charts supplied by TradingView

NewsSee all news

  1. Kitov Closes $6.0 Million Public Offering

    TEL-AVIV, March 17, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. ("Kitov") (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, today

  2. Kitov Pharma Provides Update on Planned U.S. Launch of Consensi™ and Provides Three-Year Revenue Forecast

    Company's marketing partners in the U.S. plan to commence selling Consensi in May 2020Kitov expects to receive between $28 million and $36 million in milestone and royalty revenues from 2020 through 2022 TEL AVIV,

  3. Kitov Announces Pricing of $6.0 Million Public Offering

    TEL-AVIV, Israel, March 12, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. ("Kitov") (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance,

  4. Kitov Pharma Expands Planned NT-219 Clinical Program for Difficult to Treat Cancers

    Phase 1/2 Study to Evaluate NT-219 as Monotherapy Treatment of Advanced Solid Tumors, as well as in Combination with cetuximab for Treatment of Recurrent or Metastatic Solid Tumors and Head and Neck Cancer

  5. Kitov Pharma Provides Corporate Update and Reports Full-Year 2019 Financial Results

    TEL AVIV, Israel, Feb. 11, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. ("Kitov") (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance,

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Approval announced May 31, 2018.
KIT-302
Osteoarthritis and Hypertension
Phase 1/2 trial to be initiated in 2Q 2020.
NT-219
Squamous cell carcinoma of the head & neck (SCCHN)
Phase 1/2 trial to commence 2H 2020.
CM-24 and Opdivo
Non-small cell lung cancer

Latest News

  1. Kitov Closes $6.0 Million Public Offering

    TEL-AVIV, March 17, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. ("Kitov") (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, today

  2. Kitov Pharma Provides Update on Planned U.S. Launch of Consensi™ and Provides Three-Year Revenue Forecast

    Company's marketing partners in the U.S. plan to commence selling Consensi in May 2020Kitov expects to receive between $28 million and $36 million in milestone and royalty revenues from 2020 through 2022 TEL AVIV,

  3. Kitov Announces Pricing of $6.0 Million Public Offering

    TEL-AVIV, Israel, March 12, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. ("Kitov") (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance,

  4. Kitov Pharma Expands Planned NT-219 Clinical Program for Difficult to Treat Cancers

    Phase 1/2 Study to Evaluate NT-219 as Monotherapy Treatment of Advanced Solid Tumors, as well as in Combination with cetuximab for Treatment of Recurrent or Metastatic Solid Tumors and Head and Neck Cancer

  5. Kitov Pharma Provides Corporate Update and Reports Full-Year 2019 Financial Results

    TEL AVIV, Israel, Feb. 11, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. ("Kitov") (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance,

  6. Kitov Pharma Receives Issue Notification for a U.S. Patent Covering its anti-CEACAM1 Cancer Drug, CM-24

    Patent Provides Coverage Until 2035 and Strengthens Company's IP Portfolio TEL AVIV, Israel, Feb. 03, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. ("Kitov") (NASDAQ/TASE: KTOV), a clinical-stage company advancing

  7. Kitov Pharma Receives Notice of Intention to Grant European Patent Covering the Use of NT-219 in Combination with EGFR Inhibitors

    TEL AVIV, Israel, Jan. 24, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. ("Kitov") (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance,

  8. Kitov Pharma Announces Appointment of Bertrand Liang, M.D., Ph.D., as Chief Medical Officer

    TEL AVIV, Israel, Jan. 09, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. ("Kitov") (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance,

  9. Kitov Pharma Announces Closing of FameWave Acquisition

    Concurrent with the close of the transaction, OrbiMed, Pontifax and Arkin are investing $3.5 million in Kitov and will each hold approximately 11% of the company's shares on a non-diluted basisAcquisition strengthens

  10. Kitov Pharma Granted Additional 180-day Extension by Nasdaq to Comply with Bid Price Rule

    TEL AVIV, Israel, Jan. 08, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. ("Kitov") (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance,

  11. Kitov Pharma Announces Amended Marketing and Distribution Agreement with Coeptis and Provides Update on the Upcoming Launch of Consensi™ in the U.S

    In the amended agreement with Coeptis, Kitov will receive up to $99.5M in milestone and reimbursement payments plus 20% in royaltiesCoeptis Pharmaceuticals has engaged a distribution partner with an established sales

  12. Kitov Pharma Appoints Eric K. Rowinsky, M.D., as Chairman of its Board

    Appointment of industry leader brings broad R&D Oncology Experience to Board TEL AVIV, Israel, Oct. 02, 2019 (GLOBE NEWSWIRE) --  Kitov Pharma Ltd. ("Kitov") (NASDAQ/TASE: KTOV), a clinical-stage company

  13. Kitov Pharma to Present at the H.C. Wainwright 21st Annual Healthcare Conference

    TEL AVIV, Israel, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. ("Kitov") (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance,